BVF Partners OLMA Position
Active11-Fund ConvergenceBVF Partners held their position in Olema Pharmaceuticals, Inc. (OLMA) in Q4 2025, holding $132.4M worth of shares across 5,295,893 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
OLMA is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Palazestrant in 77 days (Jun 30, 2026), making the timing of BVF's position particularly relevant.
Short interest stands at 10.2% of float with 4.1 days to cover, indicating significant bearish positioning against BVF's long thesis.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Full company profile →Short Interest
10.2%
4.1 days to cover
BVF Partners OLMA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 5,295,893 | — | $132.4M |
| Q3 2025 | Held | 5,295,893 | — | $51.8M |
| Q2 2025 | Held | 5,295,893 | — | $22.6M |
| Q1 2025 | Decreased | 5,295,893 | -420,000 | $19.9M |
| Q4 2024 | Decreased | 5,715,893 | -3,420,000 | $33.3M |
| Q3 2024 | Held | 9,135,893 | — | $109.1M |
| Q2 2024 | Held | 9,135,893 | — | $98.8M |
| Q1 2024 | Held | 9,135,893 | — | $103.4M |
| Q4 2023 | Held | 9,135,893 | — | $128.2M |
| Q3 2023 | Increased | 9,135,893 | +1,524,390 | $112.8M |
| Q2 2023 | Held | 7,611,503 | — | $68.7M |
| Q1 2023 | New | 7,611,503 | +7,611,503 | $26.4M |
Frequently Asked Questions
Does BVF Partners own OLMA?
Yes. As of Q4 2025, BVF Partners holds 5,295,893 shares of Olema Pharmaceuticals, Inc. (OLMA) valued at $132.4M. This data comes from their SEC 13F filing.
How many hedge funds own OLMA?
11 specialist biotech hedge funds currently hold OLMA, including Cormorant Asset Management, RA Capital Management, Deep Track Capital and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy OLMA?
BVF Partners's position in OLMA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's OLMA position increasing or decreasing?
BVF Partners held their OLMA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OLMACompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →